(Q37949639)

25 August 2017

title

Immunomodulatory therapy for sepsis: an update (English)

1 reference

25 August 2017

0 references

2

1 reference

25 August 2017

Eirini Christaki

1

0 references

author name string

Steven M Opal

series ordinal

3

1 reference

25 August 2017

publication date

1 November 2011

1 reference

Expert Review of Anti-infective Therapy

25 August 2017

published in

1 reference

25 August 2017

volume

9

1 reference

25 August 2017

issue

11

1 reference

25 August 2017

page(s)

1013-1033

1 reference

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Host-pathogen interactions in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Toll-like receptors in innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Molecular biology of inflammation and sepsis: a primer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Clinical review: role of triggering receptor expressed on myeloid cells-1 during sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

The IKK/NF-kappa B pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Immunologic response to infection and its role in septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Up-regulation of MyD88s and SIGIRR, molecules inhibiting Toll-like receptor signaling, in monocytes from septic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Leukocyte apoptosis and its significance in sepsis and shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Immunoparalysis and adverse outcomes from critical illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

The pathophysiology and treatment of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Beneficial effects of alkaline phosphatase in septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Bovine intestinal alkaline phosphatase attenuates the inflammatory response in secondary peritonitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Recombinant bactericidal/permeability-increasing protein inhibits endotoxin-induced high-mobility group box 1 protein gene expression in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Bactericidal/permeability-increasing protein--lessons learned from the phase III, randomized, clinical trial of rBPI21 for adjunctive treatment of children with severe meningococcemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Protective effects of lactoferrin in Escherichia coli-induced bacteremia in mice: relationship to reduced serum TNF alpha level and increased turnover of neutrophils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Lactoferrin decreases LPS-induced mitochondrial dysfunction in cultured cells and in animal endotoxemia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Endotoxin removal devices for the treatment of sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Endotoxin removal: how far from the evidence? From EUPHAS to EUPHRATES.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Endotoxin removal: how far from the evidence? The EUPHAS 2 Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

A novel adsorbent of circulating bacterial toxins and cytokines: the effect of direct hemoperfusion with CTR column for the treatment of experimental endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Reversing established sepsis with antagonists of endogenous high-mobility group box 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

CKD712, (S)-1-(α-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, inhibits the lipopolysaccharide-stimulated secretion of HMGB1 by inhibiting PI3K and classical protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

The inhibitory effect of lidocaine on the release of high mobility group box 1 in lipopolysaccharide-stimulated macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Suppression of HMGB1 release by stearoyl lysophosphatidylcholine:an additional mechanism for its therapeutic effects in experimental sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Blood and plasma treatments: the rationale of high-volume hemofiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Hemofiltration with the Cascade system in an experimental porcine model of septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

A pilot study of coupled plasma filtration with adsorption in septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Effects of hemoadsorption on cytokine removal and short-term survival in septic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Renal assist device and treatment of sepsis-induced acute kidney injury in intensive care units

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Efficacy and safety of renal tubule cell therapy for acute renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Thymosin alpha1- and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

The critical role of adenosine A2A receptors in downregulation of inflammation and immunity in the pathogenesis of infectious diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Adenosine A(2A) receptor agonist (CGS-21680) prevents endotoxin-induced effects on nucleotidase activities in mouse lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

An A2A adenosine receptor agonist, ATL313, reduces inflammation and improves survival in murine sepsis models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Endotoxin tolerance and cross-tolerance in mast cells involves TLR4, TLR2 and FcepsilonR1 interactions and SOCS expression: perspectives on immunomodulation in infectious and allergic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor-{gamma}

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, reduces acute lung injury in endotoxemic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Agonist of peroxisome proliferator-activated receptor-gamma, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Pretreatment of curcumin attenuates coagulopathy and renal injury in LPS-induced endotoxemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Curcumin attenuates the organ dysfunction caused by endotoxemia in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Pharmacologic cholinesterase inhibition improves survival in experimental sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Inhibition of bacterial superantigens by peptides and antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Role of chemically modified tetracycline on TNF-alpha and mitogen-activated protein kinases in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

The anti-inflammatory activity of clarithromycin inhibits TNFalpha production and prolongs survival following lipopolysaccharide administration in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Statin treatment after onset of sepsis in a murine model improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

The effect of statins on mortality in patients with bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Understanding the potential role of statins in pneumonia and sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Statins do not prevent acute organ failure in ventilated ICU patients: single-centre retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

High C5a levels are associated with increased mortality in sepsis patients--no enhancing effect by actin-free Gc-globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Protective effects of C5a blockade in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

C1 inhibitor treatment improves host defense in pneumococcal meningitis in rats and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

C1-esterase inhibitor attenuates the inflammatory response during human endotoxemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Exogenous platelet-activating factor acetylhydrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Bench-to-bedside review: Cytopathic hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Protective effect of a novel, potent inhibitor of poly(adenosine 5'-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Selenium and inflammation: underlying anti-inflammatory mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Randomised trial of glutamine, selenium, or both, to supplement parenteral nutrition for critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Post-treatment with N-acetylcysteine ameliorates endotoxin shock-induced organ damage in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Apoptosis and caspases regulate death and inflammation in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

The sepsis seesaw: tilting toward immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Increased mortality in long-term intensive care patients with active cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Enhancement of neutrophil function by in vivo filgrastim treatment for prophylaxis of sepsis in surgical intensive care patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Dose-dependent effect of anti-CTLA-4 on survival in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Alveolar macrophage deactivation in murine septic peritonitis: role of interleukin 10

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Characterization and modulation of the immunosuppressive phase of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Inhibition of Fas/Fas ligand signaling improves septic survival: differential effects on macrophage apoptotic and functional capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

A randomized trial of isonitrogenous enteral diets after severe trauma. An immune-enhancing diet reduces septic complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Randomised trial of glutamine-enriched enteral nutrition on infectious morbidity in patients with multiple trauma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Why do animal models (sometimes) fail to mimic human sepsis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

The use of immunocompromised animals as models for human septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Concept of PIRO as a new conceptual framework to understand sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Cytokines and anticytokines in the pathogenesis of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Sepsis-induced immunosuppression: from bad to worse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

Emergence of autoantibodies to HMGB1 is associated with survival in patients with septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.11.122

21 January 2018

Identifiers

DOI

10.1586/ERI.11.122

1 reference

25 August 2017

1 reference